1
|
Samouilidou EC, Liaouri A, Kostopoulos V, Nikas D, Grapsa E. The importance of paraoxonase 1 activity in chronic kidney disease. Ren Fail 2024; 46:2376930. [PMID: 38982880 PMCID: PMC11238655 DOI: 10.1080/0886022x.2024.2376930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 07/02/2024] [Indexed: 07/11/2024] Open
Abstract
Paraoxonase 1 (PON1) is one of the most significant antioxidative enzymes associated with high-density lipoprotein (HDL). It has been proved that is involved in the pathogenesis of many diseases including chronic kidney disease (CKD). The association between PON1 and CKD seems to be mutual, such that the disease produces a significant decrease in PON1 activity levels, while the genetics of PON1 may affect the risk of susceptibility to CKD. Recent studies reveal that the decrease in serum PON1 activity observed in non-dialyzed and dialyzed CKD patients as well as in renal transplant (RT) patients is linked to an increased vulnerability to atherosclerosis. We intend to summarize current literature concerning PON1 activity in CKD, highlighting on the main determinants of PON1 activity, its association with oxidative stress, the impact of its genetic polymorphism on the disease development, the effect of drugs and nutritional state. Furthermore, evidence supporting the implication of reduced PON1 activity in the incident of cardiovascular disease in CKD patients, is also examined. It appears that despite the lack of standardization of PON1 activity measurement, PON1 remains a valuable biomarker for the researchers through the last decades, which contributes to the assessment of the antioxidant status having prognostic benefit on adverse clinical outcomes at various stages and etiologies of kidney disease.
Collapse
Affiliation(s)
| | | | | | - Dimitris Nikas
- Department of Biochemistry, "Alexandra" Hospital, Athens, Greece
| | | |
Collapse
|
2
|
Dube P, Khalaf FK, DeRiso A, Mohammed CJ, Connolly JA, Battepati D, Lad A, Breidenbach JD, Kleinhenz AL, Khatib-Shahidi B, Patel M, Tassavvor I, Gohara AF, Malhotra D, Morgan EE, Haller ST, Kennedy DJ. Cardioprotective Role for Paraoxonase-1 in Chronic Kidney Disease. Biomedicines 2022; 10:2301. [PMID: 36140402 PMCID: PMC9496500 DOI: 10.3390/biomedicines10092301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 09/05/2022] [Accepted: 09/07/2022] [Indexed: 11/17/2022] Open
Abstract
Paraoxonase-1 (PON-1) is a hydrolytic enzyme associated with HDL, contributing to its anti-inflammatory, antioxidant, and anti-atherogenic properties. Deficiencies in PON-1 activity result in oxidative stress and detrimental clinical outcomes in the context of chronic kidney disease (CKD). However, it is unclear if a decrease in PON-1 activity is mechanistically linked to adverse cardiovascular events in CKD. We investigated the hypothesis that PON-1 is cardioprotective in a Dahl salt-sensitive model of hypertensive renal disease. Experiments were performed on control Dahl salt-sensitive rats (SSMcwi, hereafter designated SS-WT rats) and mutant PON-1 rats (SS-Pon1em1Mcwi, hereafter designated SS-PON-1 KO rats) generated using CRISPR gene editing technology. Age-matched 10-week-old SS and SS-PON-1 KO male rats were maintained on high-salt diets (8% NaCl) for five weeks to induce hypertensive renal disease. Echocardiography showed that SS-PON-1 KO rats but not SS-WT rats developed compensated left ventricular hypertrophy after only 4 weeks on the high-salt diet. RT-PCR analysis demonstrated a significant increase in the expression of genes linked to cardiac hypertrophy, inflammation, and fibrosis, as well as a significant decrease in genes essential to left ventricular function in SS-PON-1 KO rats compared to SS-WT rats. A histological examination also revealed a significant increase in cardiac fibrosis and immune cell infiltration in SS-PON-1 KO rats, consistent with their cardiac hypertrophy phenotype. Our data suggest that a loss of PON-1 in the salt-sensitive hypertensive model of CKD leads to increased cardiac inflammation and fibrosis as well as a molecular and functional cardiac phenotype consistent with compensated left ventricular hypertrophy.
Collapse
Affiliation(s)
- Prabhatchandra Dube
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Fatimah K. Khalaf
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
- Department of Clinical Pharmacy, University of Alkafeel, Najaf 54001, Iraq
| | - Armelle DeRiso
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Chrysan J. Mohammed
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Jacob A. Connolly
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Dhanushya Battepati
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Apurva Lad
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Joshua D. Breidenbach
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Andrew L. Kleinhenz
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Bella Khatib-Shahidi
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Mitra Patel
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Iman Tassavvor
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Amira F. Gohara
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Deepak Malhotra
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - Eric E. Morgan
- Department of Surgery, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43606, USA
| | - Steven T. Haller
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| | - David J. Kennedy
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA
| |
Collapse
|
3
|
Khalaf FK, Mohammed CJ, Dube P, Connolly JA, Lad A, Ashraf UM, Breidenbach JD, Su RC, Kleinhenz AL, Malhotra D, Gohara AF, Haller ST, Kennedy DJ. Paraoxonase-1 Regulation of Renal Inflammation and Fibrosis in Chronic Kidney Disease. Antioxidants (Basel) 2022; 11:antiox11050900. [PMID: 35624764 PMCID: PMC9137734 DOI: 10.3390/antiox11050900] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 04/27/2022] [Accepted: 04/27/2022] [Indexed: 12/04/2022] Open
Abstract
Papraoxonase-1 (PON1) is a hydrolytic lactonase enzyme that is synthesized in the liver and circulates attached to high-density lipoproteins (HDL). Clinical studies have demonstrated an association between diminished PON-1 and the progression of chronic kidney disease (CKD). However, whether decreased PON-1 is mechanistically linked to renal injury is unknown. We tested the hypothesis that the absence of PON-1 is mechanistically linked to the progression of renal inflammation and injury in CKD. Experiments were performed on control Dahl salt-sensitive rats (SSMcwi, hereafter designated SS rats) and Pon1 knock-out rats (designated SS-Pon1em1Mcwi, hereafter designated SS-PON-1 KO rats) generated by injecting a CRISPR targeting the sequence into SSMcwi rat embryos. The resulting mutation is a 7 bp frameshift insertion in exon 4 of the PON-1 gene. First, to examine the renal protective role of PON-1 in settings of CKD, ten-week-old, age-matched male rats were maintained on a high-salt diet (8% NaCl) for up to 5 weeks to initiate the salt-sensitive hypertensive renal disease characteristic of this model. We found that SS-PON-1 KO rats demonstrated several hallmarks of increased renal injury vs. SS rats including increased renal fibrosis, sclerosis, and tubular injury. SS-PON-1 KO also demonstrated increased recruitment of immune cells in the renal interstitium, as well as increased expression of inflammatory genes compared to SS rats (all p < 0.05). SS-PON-1 KO rats also showed a significant (p < 0.05) decline in renal function and increased renal oxidative stress compared to SS rats, despite no differences in blood pressure between the two groups. These findings suggest a new role for PON-1 in regulating renal inflammation and fibrosis in the setting of chronic renal disease independent of blood pressure.
Collapse
Affiliation(s)
- Fatimah K. Khalaf
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
- Department of Clinical Pharmacy, University of Alkafeel, Najaf 54001, Iraq
| | - Chrysan J. Mohammed
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Prabhatchandra Dube
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Jacob A. Connolly
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Apurva Lad
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Usman M. Ashraf
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Joshua D. Breidenbach
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Robin C. Su
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Andrew L. Kleinhenz
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Deepak Malhotra
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Amira F. Gohara
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - Steven T. Haller
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
| | - David J. Kennedy
- Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43606, USA; (F.K.K.); (C.J.M.); (P.D.); (J.A.C.); (A.L.); (U.M.A.); (J.D.B.); (R.C.S.); (A.L.K.); (D.M.); (A.F.G.); (S.T.H.)
- Correspondence: ; Tel.: +1-419-383-6822
| |
Collapse
|
4
|
Connelly PW, Yan AT, Nash MM, Wald RM, Lok C, Gunaratnam L, Kirpalani A, Prasad GVR. The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients. Front Cardiovasc Med 2021; 8:763389. [PMID: 34926614 PMCID: PMC8674585 DOI: 10.3389/fcvm.2021.763389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 10/20/2021] [Indexed: 11/26/2022] Open
Abstract
Background: Patients on dialysis have impaired cardiac function, in part due to increased fluid volume and ventricular stress. Restored kidney function through transplantation reduces left ventricular volume in both systole and diastole. We previously reported that the decrease in NT-proB-type natriuretic peptide (NT-proBNP) was associated with a decrease in adiponectin. Paraoxonase 1 (PON1) has been inversely associated with cardiovascular outcomes. We now report the association of changes in PON1 with changes in left ventricular volume and left ventricular mass after kidney transplantation. Design: Patients on dialysis were assessed at baseline and 12 months after kidney transplantation (n = 38). A comparison group of patients on dialysis who were not expected to receive a transplant in the next 24 months were studied (n = 43) to determine if the change of PON1 with kidney transplantation achieved a significance greater than that due to biologic variation. Left ventricular volume and mass were determined by cardiac magnetic resonance imaging. PON1 was measured by arylesterase activity and by mass. Results: PON1 mass and activity were not different between the groups at baseline. Both PON1 mass and activity were increased post-kidney transplantation (p < 0.0001 for change). The change in PON1 mass (p = 0.0062) and PON1 arylesterase activity (p = 0.0254) were inversely correlated with the change in NT-proBNP for patients receiving a kidney transplant. However, only the change in the PON1 mass, and not the change in PON1 arylesterase, was inversely correlated with the change in left ventricular volume (ml/m2.7) (p = 0.0146 and 0.0114 for diastolic and systolic, respectively) and with the change in hemoglobin (p = 0.0042). Conclusion: Both PON1 mass and arylesterase activity are increased by kidney transplantation. The increase in PON1 mass is consistent with a novel relationship to the increase in hemoglobin and decrease in left ventricular volume and NT-proBNP seen when kidney function is restored.
Collapse
Affiliation(s)
- Philip W Connelly
- Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.,Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, ON, Canada
| | - Andrew T Yan
- Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | - Michelle M Nash
- Kidney Transplant Program, St. Michael's Hospital, Toronto, ON, Canada
| | - Rachel M Wald
- Division of Cardiology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
| | - Charmaine Lok
- Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
| | - Lakshman Gunaratnam
- Division of Nephrology, London Health Sciences Centre, Western University, London, ON, Canada
| | - Anish Kirpalani
- Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | - G V Ramesh Prasad
- Kidney Transplant Program, St. Michael's Hospital, Toronto, ON, Canada
| |
Collapse
|
5
|
Grzegorzewska AE, Adamska P, Iwańczyk-Skalska E, Ostromecka K, Niepolski L, Marcinkowski W, Mostowska A, Warchoł W, Żaba C, Jagodziński PP. Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients. Sci Rep 2021; 11:6773. [PMID: 33762698 PMCID: PMC7990965 DOI: 10.1038/s41598-021-86231-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 02/23/2021] [Indexed: 01/31/2023] Open
Abstract
Paraoxonase 1 (PON1) is known for preventing atherosclerosis through lipid-modifying features, antioxidant activity, anti-inflammatory, anti-apoptosis, anti-thrombosis, and anti-adhesion properties. Uremic patients requiring haemodialysis (HD) are especially prone to atherosclerosis and its complications. We analysed the PON1 gene (PON1) polymorphisms and serum PON1 (paraoxonase) activity concerning dyslipidaemia and related cardiovascular diseases and mortality to show how they associate under uremic conditions modified by maintenance HD treatment. The rs662 AA + AG (OR 1.76, 95%CI 1.10-2.80, P = 0.018), rs854560 TT (OR 1.48, 95%CI 1.04-2.11, P = 0.031), and rs854560 AT + TT (OR 1.28, 95%CI 1.01-1.63, P = 0.040) contributed to the prevalence of atherogenic dyslipidaemia diagnosed by the triglyceride (TG)/HDL-cholesterol ratio ≥ 3.8. The normalized serum PON1 activity positively correlated with atherogenic dyslipidaemia (ẞ 0.67 ± 0.25, P = 0.008). The PON1 rs854560 allele T was involved in the higher prevalence of ischemic cerebral stroke (OR 1.38, 1.02-1.85, P = 0.034). The PON1 rs705379 TT genotype contributed to cardiovascular (HR 1.27, 95% CI 1.03-1.57, P = 0.025) and cardiac (HR 1.34, 95% CI 1.05-1.71, P = 0.018) mortality. All P-values were obtained in multiple regression analyses, including clinical variables. Multifaceted associations of PON1 with dyslipidaemia, ischemic cerebral stroke, and cardiovascular mortality in HD patients provide arguments for the consideration of PON1 and its protein product as therapeutic targets in the prevention of atherosclerosis and its complications in uremic patients.
Collapse
Affiliation(s)
- Alicja E. Grzegorzewska
- grid.22254.330000 0001 2205 0971Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznań, Poland
| | - Paulina Adamska
- grid.22254.330000 0001 2205 0971Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznań, Poland
| | - Ewa Iwańczyk-Skalska
- grid.22254.330000 0001 2205 0971Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznań, Poland
| | - Kamila Ostromecka
- grid.22254.330000 0001 2205 0971Nephrology Research Group, Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland
| | - Leszek Niepolski
- B. Braun Avitum Poland, Dialysis Center, 64-300 Nowy Tomyśl, Poland
| | | | - Adrianna Mostowska
- grid.22254.330000 0001 2205 0971Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznań, Poland
| | - Wojciech Warchoł
- grid.22254.330000 0001 2205 0971Department of Ophthalmology and Optometry, Poznan University of Medical Sciences, 60-806 Poznań, Poland
| | - Czesław Żaba
- grid.22254.330000 0001 2205 0971Department of Forensic Medicine, Poznan University of Medical Sciences, 60-781 Poznań, Poland
| | - Paweł P. Jagodziński
- grid.22254.330000 0001 2205 0971Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznań, Poland
| |
Collapse
|
6
|
Marsillach J, Adorni MP, Zimetti F, Papotti B, Zuliani G, Cervellati C. HDL Proteome and Alzheimer's Disease: Evidence of a Link. Antioxidants (Basel) 2020; 9:E1224. [PMID: 33287338 PMCID: PMC7761753 DOI: 10.3390/antiox9121224] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 11/25/2020] [Accepted: 11/30/2020] [Indexed: 12/16/2022] Open
Abstract
Several lines of epidemiological evidence link increased levels of high-density lipoprotein-cholesterol (HDL-C) with lower risk of Alzheimer's disease (AD). This observed relationship might reflect the beneficial effects of HDL on the cardiovascular system, likely due to the implication of vascular dysregulation in AD development. The atheroprotective properties of this lipoprotein are mostly due to its proteome. In particular, apolipoprotein (Apo) A-I, E, and J and the antioxidant accessory protein paraoxonase 1 (PON1), are the main determinants of the biological function of HDL. Intriguingly, these HDL constituent proteins are also present in the brain, either from in situ expression, or derived from the periphery. Growing preclinical evidence suggests that these HDL proteins may prevent the aberrant changes in the brain that characterize AD pathogenesis. In the present review, we summarize and critically examine the current state of knowledge on the role of these atheroprotective HDL-associated proteins in AD pathogenesis and physiopathology.
Collapse
Affiliation(s)
- Judit Marsillach
- Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA 98195, USA;
| | - Maria Pia Adorni
- Unit of Neurosciences, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy;
| | - Francesca Zimetti
- Department of Food and Drug, University of Parma, 43124 Parma, Italy;
| | - Bianca Papotti
- Department of Food and Drug, University of Parma, 43124 Parma, Italy;
| | - Giovanni Zuliani
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; (G.Z.); (C.C.)
| | - Carlo Cervellati
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; (G.Z.); (C.C.)
| |
Collapse
|
7
|
Grzegorzewska AE, Ostromecka K, Adamska P, Mostowska A, Warchoł W, Jagodziński PP. Paraoxonase 1 gene polymorphisms concerning non-insulin-dependent diabetes mellitus nephropathy in hemodialysis patients. J Diabetes Complications 2020; 34:107687. [PMID: 32855040 DOI: 10.1016/j.jdiacomp.2020.107687] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 05/30/2020] [Accepted: 07/18/2020] [Indexed: 01/21/2023]
Abstract
AIMS Data on involvement of paraoxonase 1 gene (PON1) in non-insulin-dependent diabetes mellitus (NIDDM) nephropathy are scarce. We investigated PON1 polymorphisms concerning end-stage NIDDM nephropathy and atherosclerotic complications in NIDDM nephropathy patients treated with hemodialysis (HD). METHODS In NIDDM nephropathy (n = 402) and non-diabetic (n = 998) HD subjects, we obtained PON1 polymorphisms by HRM analysis (rs662) or predesigned TaqMan SNV Genotyping Assay (rs854560, rs705379). RESULTS Only PON1 rs705379 was associated with end-stage NIDDM nephropathy in the recessive (OR 1.451, 95% CI 1.104-1.906, P = 0.009) and additive (OR 1.398, 95%CI 1.009-1.936, P = 0.046) inheritance modes. NIDDM nephropathy patients bearing the rs854560 T allele were at higher risk for ischemic cerebral stroke (OR 2.087, 95%CI 1.145-3.801, P = 0.016). In non-diabetic patients but not NIDDM nephropathy subjects, atherogenic dyslipidemia corresponded with PON1 rs662 A allele and PON1 rs854560 TT homozygosity. CONCLUSIONS In HD patients, NIDDM nephropathy correlates with the TT genotype of PON1 rs705379. The rs854560 T allele indicates a higher risk for atherosclerotic diseases in NIDDM nephropathy subjects. The T alleles of both PON1 SNVs are known as low expression variants downregulated serum PON1 activity. An increase of diminished PON1 activity may be a target in the prevention of NIDDM nephropathy and NIDDM atherosclerotic complications.
Collapse
Affiliation(s)
- Alicja E Grzegorzewska
- Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Przybyszewskiego 49, Poland.
| | - Kamila Ostromecka
- Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Przybyszewskiego 49, Poland
| | - Paulina Adamska
- Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Przybyszewskiego 49, Poland
| | - Adrianna Mostowska
- Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznań, Święcickiego 6, Poland
| | - Wojciech Warchoł
- B. Braun Avitum Poland, Dialysis Center, 64-300 Nowy Tomyśl, Sienkiewicza 3, Poland; Department of Ophthalmology and Optometry, Poznan University of Medical Sciences, Poznań, Poland.
| | - Paweł P Jagodziński
- Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznań, Święcickiego 6, Poland.
| |
Collapse
|
8
|
Samouilidou E, Bountou E, Papandroulaki F, Papamanolis M, Papakostas D, Grapsa E. Serum Endocan Levels are Associated With Paraoxonase 1 Concentration in Patients With Chronic Kidney Disease. Ther Apher Dial 2018; 22:325-331. [PMID: 29368426 DOI: 10.1111/1744-9987.12654] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 10/01/2017] [Accepted: 10/26/2017] [Indexed: 01/30/2023]
Abstract
Endocan is a soluble proteoglycan released by the vascular endothelium. The increase of its serum levels is associated with inflammation, endothelial dysfunction and cardiovascular events in patients with chronic kidney disease (CKD). We studied the association of serum endocan with the lipid profile of 105 CKD patients with dyslipidemia, divided in two groups, non-dialyzed (CKD, N = 57) and hemodialysis (HD, N = 48) in comparison with 30 normal controls (NC). We also analyzed endocan in relation with the concentration of two serum HDL-linked members of the paraoxonase (PON) family, PON1 and PON3, which have been previously found to have antiatherogenic properties. The results showed that endocan levels were significantly higher in HD patients than in CKD patients (P < 0.001) and NC (P < 0.001). PON1 was significantly decreased only in HD patients compared to NC (P < 0.001), whereas PON3 was significantly increased in both patient groups (P < 0.001). Endocan levels were significantly and positively correlated with total cholesterol and LDL-C in CKD and additionally were negatively correlated with HDL-C in HD group. PON1 levels were significantly correlated with endocan in both groups, while no correlation was observed for PON3 in either group. Multiple regression analysis between endocan and the above lipid parameters in the total of patients revealed that endocan was independently associated only with PON1 (β = -0.513, P = 0.002). It is concluded that the increase of serum endocan levels in patients with CKD may be associated with the decrease of PON1 concentration, irrespective of lipid alterations produced by atherosclerosis development.
Collapse
Affiliation(s)
| | - Eirini Bountou
- Nephrology Department, "Aretaeio" University Hospital, Athens, Greece
| | | | | | | | - Eirini Grapsa
- Nephrology Department, "Aretaeio" University Hospital, Athens, Greece
| |
Collapse
|
9
|
Costa LG, Cole TB, Garrick JM, Marsillach J, Furlong CE. Metals and Paraoxonases. ADVANCES IN NEUROBIOLOGY 2017; 18:85-111. [PMID: 28889264 DOI: 10.1007/978-3-319-60189-2_5] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The paraoxonases (PONs) are a three-gene family which includes PON1, PON2, and PON3. PON1 and PON3 are synthesized primarily in the liver and a portion is secreted in the plasma, where they are associated with high-density lipoproteins (HDLs), while PON2 is an intracellular enzyme, expressed in most tissues and organs, including the brain. PON1 received its name from its ability to hydrolyze paraoxon, the active metabolite of the organophosphorus (OP) insecticide parathion, and also more efficiently hydrolyzes the active metabolites of several other OPs. PON2 and PON3 do not have OP-esterase activity, but all PONs are lactonases and are capable of hydrolyzing a variety of lactones, including certain drugs, endogenous compounds, and quorum-sensing signals of pathogenic bacteria. In addition, all PONs exert potent antioxidant effects. PONs play important roles in cardiovascular diseases and other oxidative stress-related diseases, modulate susceptibility to infection, and may provide neuroprotection (PON2). Hence, significant attention has been devoted to their modulation by a variety of dietary, pharmacological, lifestyle, or environmental factors. A number of metals have been shown in in vitro, animal, and human studies to mostly negatively modulate expression of PONs, particularly PON1, the most studied in this regard. In addition, different levels of expression of PONs may affect susceptibility to toxicity and neurotoxicity of metals due to their aforementioned antioxidant properties.
Collapse
Affiliation(s)
- Lucio G Costa
- Department of Environmental and Occupational Health Sciences, University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA. .,Department of Medicine & Surgery, University of Parma, Parma, Italy.
| | - Toby B Cole
- Department of Environmental and Occupational Health Sciences, University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA.,Center on Human Development and Disability, University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA
| | - Jacqueline M Garrick
- Department of Environmental and Occupational Health Sciences, University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA
| | - Judit Marsillach
- Department of Medicine (Division of Medical Genetics), University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA
| | - Clement E Furlong
- Department of Medicine (Division of Medical Genetics), University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA.,Department of Genome Sciences, University of Washington, 4225 Roosevelt Way NE, Suite 100, Seattle, WA, 98105, USA
| |
Collapse
|
10
|
Systemic Redox Imbalance in Chronic Kidney Disease: A Systematic Review. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2016; 2016:8598253. [PMID: 27563376 PMCID: PMC4987477 DOI: 10.1155/2016/8598253] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 05/31/2016] [Accepted: 06/07/2016] [Indexed: 01/01/2023]
Abstract
Patients with chronic kidney disease (CKD) experience imbalance between oxygen reactive species (ROS) production and antioxidant defenses leading to cell and tissue damage. However, it remains unclear at which stage of renal insufficiency the redox imbalance becomes more profound. The aim of this systematic review was to provide an update on recent advances in our understanding of how the redox status changes in the progression of renal disease from predialysis stages 1 to 4 to end stage 5 and whether the various treatments and dialysis modalities influence the redox balance. A systematic review was conducted searching PubMed and Scopus by using the Cochrane and PRISMA guidelines. In total, thirty-nine studies met the inclusion criteria and were reviewed. Even from an early stage, imbalance in redox status is evident and as the kidney function worsens it becomes more profound. Hemodialysis therapy per se seems to negatively influence the redox status by the elevation of lipid peroxidation markers, protein carbonylation, and impairing erythrocyte antioxidant defense. However, other dialysis modalities do not so far appear to confer advantages. Supplementation with antioxidants might assist and should be considered as an early intervention to halt premature atherogenesis development at an early stage of CKD.
Collapse
|
11
|
Fort-Gallifa I, García-Heredia A, Hernández-Aguilera A, Simó JM, Sepúlveda J, Martín-Paredero V, Camps J, Joven J. Biochemical indices of oxidative stress and inflammation in the evaluation of peripheral artery disease. Free Radic Biol Med 2016; 97:568-576. [PMID: 27449545 DOI: 10.1016/j.freeradbiomed.2016.07.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 05/24/2016] [Accepted: 07/14/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND The aims of this study were: (1) to investigate changes in indices of oxidative stress and inflammation in the evaluation of peripheral artery disease (PAD); (2) to compare the diagnostic efficacy of these parameters with that of classical clinical laboratory routine parameters. DESIGN AND METHODS We studied 115 patients with PAD and 300 healthy volunteers. RESULTS PAD patients had significantly increased circulating concentrations of F2-isoprostanes, protein carbonyls, chemokine (C-C motif) ligand 2 (CCL2), high-sensitivity C-reactive protein (hs-CRP), β-2-microglobulin (B2M), and decreased paraoxonase-1 (PON1) levels. When patients were classified according to the Fontaine score, we observed important increases in plasma F2-isoprostanes and CCL2 that appeared in milder stages of the disease, and remained so at similar levels in more advanced stages; almost no overlapping with the control group was noted. Receiver operating characteristics analysis comparing patients and controls revealed that the areas under the curve for F2-isoprostanes and CCL2 approached unity [0.999 (0.998-1.000) and 0.993 (0.985-1.000)], respectively, and significantly higher to those of the other measured parameters. CONCLUSION Our data suggest that F2-isoprostanes and CCL2 measurements may be useful tools for the diagnosis of PAD.
Collapse
Affiliation(s)
- Isabel Fort-Gallifa
- Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain; Laboratori de Referència de Catalunya SUD, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
| | - Anabel García-Heredia
- Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
| | - Anna Hernández-Aguilera
- Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
| | - Josep M Simó
- Laboratori de Referència de Catalunya SUD, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
| | - Julio Sepúlveda
- Servei d'Angiologia, Cirurgia Vascular i Endocirurgia, Hospital Universitari Joan XXIII, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain
| | - Vicente Martín-Paredero
- Servei d'Angiologia, Cirurgia Vascular i Endocirurgia, Hospital Universitari Joan XXIII, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain
| | - Jordi Camps
- Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain.
| | - Jorge Joven
- Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
| |
Collapse
|
12
|
Samouilidou E, Kostopoulos V, Liaouri A, Kioussi E, Vassiliou K, Bountou E, Grapsa E. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease. Ren Fail 2016; 38:1601-1606. [DOI: 10.3109/0886022x.2016.1144031] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Affiliation(s)
| | | | | | - Eva Kioussi
- Nephrology Department, “Aretaeio” University Hospital, Athens, Greece
| | | | - Eirini Bountou
- Nephrology Department, “Aretaeio” University Hospital, Athens, Greece
| | - Eirini Grapsa
- Nephrology Department, “Aretaeio” University Hospital, Athens, Greece
| |
Collapse
|
13
|
Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015; 60:50-73. [DOI: 10.1016/j.plipres.2015.08.003] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Revised: 08/08/2015] [Accepted: 08/30/2015] [Indexed: 12/20/2022]
|
14
|
Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis. BIOMED RESEARCH INTERNATIONAL 2014; 2014:175286. [PMID: 25276769 PMCID: PMC4174976 DOI: 10.1155/2014/175286] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Accepted: 08/19/2014] [Indexed: 12/18/2022]
Abstract
We evaluated the potential cardiovascular risk protection of bilirubin in hemodialysis (HD) patients. An enlarged set of studies were evaluated in 191 HD patients, including hematological study, lipid profile, iron metabolism, nutritional, inflammatory markers, and dialysis adequacy. The TA duplication screening in the UDP-glucuronosyltransferase 1 A1 (UGT1A1) promoter region was also performed. The UGT1A1 genotype frequencies in HD patients were 49.2%, 42.4%, and 8.4% for 6/6, 6/7, and 7/7 genotypes, respectively. Although no difference was found in UGT1A1 genotype distribution between the three tertiles of bilirubin, significant differences were found with increasing bilirubin levels, namely, a decrease in platelet, leukocyte, and lymphocyte counts, transferrin, oxidized low-density lipoprotein (ox-LDL), ox-LDL/low-density lipoprotein cholesterol ratio, apolipoprotein (Apo) A, Apo B, and interleukin-6 serum levels and a significant increased concentration of hemoglobin, hematocrit, erythrocyte count, iron, transferrin saturation, Apo A/Apo B ratio, adiponectin, and paraoxonase 1 serum levels. After adjustment for age these results remained significant. Our data suggest that higher bilirubin levels are associated with beneficial effects in HD patients, by improving lipid profile and reducing the inflammatory grade, which might contribute to increase in iron availability. These results suggest a potential cardiovascular risk protection of bilirubin in HD patients.
Collapse
|
15
|
Kim DS, Marsillach J, Furlong CE, Jarvik GP. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 2014; 14:1495-515. [PMID: 24024900 DOI: 10.2217/pgs.13.147] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of substrates, including toxic organophosphorous compounds, statin adducts, glucocorticoids, the likely atherogenic L-homocysteine thiolactone and the quorum-sensing factor of Pseudomonas aeruginosa. Numerous cardiovascular and antidiabetic pharmacologic agents, dietary macronutrients, lifestyle factors and antioxidant supplements affect PON1 expression and enzyme activity levels. Owing to the importance of PON1 to HDL function and its individual association with diverse human diseases, pharmacogenomic interactions between PON1 and the various factors that alter its expression and activity may represent an important therapeutic target for future investigation.
Collapse
Affiliation(s)
- Daniel Seung Kim
- Departments of Genome Sciences & Medicine (Division of Medical Genetics), University of Washington School of Medicine, Box 357720, University of Washington, Seattle, WA 98195-7720, USA
| | | | | | | |
Collapse
|
16
|
Martinelli N, Consoli L, Girelli D, Grison E, Corrocher R, Olivieri O. Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease. Adv Clin Chem 2013; 59:65-100. [PMID: 23461133 DOI: 10.1016/b978-0-12-405211-6.00003-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Interest in the role of paraoxonases (PON) in cardiovascular research has increased substantially over the past two decades. These multifaceted and pleiotropic enzymes are encoded by three highly conserved genes (PON1, PON2, and PON3) located on chromosome 7q21.3-22.1. Phylogenetic analysis suggests that PON2 is the ancient gene from which PON1 and PON3 arose via gene duplication. Although PON are primarily lactonases with overlapping, but distinct specificities, their physiologic substrates remain poorly characterized. The most interesting characteristic of PON, however, is their multifunctional roles in various biochemical pathways. These include protection against oxidative damage and lipid peroxidation, contribution to innate immunity, detoxification of reactive molecules, bioactivation of drugs, modulation of endoplasmic reticulum stress, and regulation of cell proliferation/apoptosis. In general, PON appear as "hunters" of old and new substrates often involved in athero- and thrombogenesis. Although reduced PON activity appears associated with increased cardiovascular risk, the correlation between PON genotype and ischemic heart disease remains controversial. In this review, we examine the biochemical pathways impacted by these unique enzymes and investigate the potential use of PON as diagnostic tools and their impact on development of future therapeutic strategies.
Collapse
Affiliation(s)
- Nicola Martinelli
- Department of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy.
| | | | | | | | | | | |
Collapse
|
17
|
Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, Freitas I, Mendonça MI, Nascimento H, Rocha-Pereira P, Miranda V, Mendonça D, Quintanilha A, Belo L, Costa E, Reis F, Santos-Silva A. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol 2012; 36:317-23. [PMID: 23007074 DOI: 10.1159/000342235] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Accepted: 07/30/2012] [Indexed: 12/12/2022]
Abstract
BACKGROUND/AIMS Cardiovascular diseases are the major cause of morbidity and mortality in hemodialysis (HD) patients. These patients present reduced paraoxonase 1 (PON1) activity that depends on genetic and non-genetic factors; however, how these factors influence PON1 activity in HD patients is poorly clarified. Our aim was to evaluate the influence of two polymorphisms and non-genetic factors on PON1 activity in HD patients. METHODS We evaluated 183 HD patients under recombinant human erythropoietin (rhEPO) treatment and 22 healthy individuals. The lipid profile [total cholesterol, triglycerides, HDL-c, LDL-c, apolipoprotein (Apo) A-I, Apo B, lipoprotein(a) and oxidized low-density lipoprotein (Ox-LDL)], inflammatory markers [adiponectin, interleukin-6 (IL-6) and C-reactive protein (CRP)], PON1 activity and PON1 gene polymorphisms (L55M and Q192R) were evaluated. RESULTS HD patients presented higher levels of IL-6, CRP and Ox-LDL/LDL-c, and lower PON1 activity, total cholesterol, HDL-c, LDL-c, Apo A and Apo B; the most frequent genotype was heterozygosity for L55M polymorphism and homozygosity for the Q allele, the more frequent genotype of Q192R polymorphism. Multiple regression analysis identified heterozygosity and homozygosity for L55M and Q192R polymorphisms, very low-density lipoproteins, LDL-c, Apo A and CRP levels, time on dialysis and rhEPO dose, as the independent variables significantly associated with PON1 activity. The associations with CRP, rhEPO and time on dialysis were negative. CONCLUSION Our results show that the reduced PON1 activity in HD patients who are not under statin therapy is strongly associated with inflammation, longer time on dialysis and high rhEPO doses, suggesting that the reduction in PON1 activity may worsen the prognosis of these patients.
Collapse
|
18
|
Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients. Int Urol Nephrol 2012; 45:441-7. [PMID: 22669508 DOI: 10.1007/s11255-012-0197-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2012] [Accepted: 05/09/2012] [Indexed: 01/02/2023]
Abstract
Atherosclerosis is an important contributor to increased cardiovascular burden in populations with and without renal disease. Paraoxonases (PON) are a group of enzymes that hydrolyse organophosphates. Recent evidence indicates a protective role for PON in patients with coronary artery disease and atherosclerosis. Although data are limited, the low enzyme activity found in patients with chronic kidney disease and renal transplants has been linked to atherosclerosis and arterial stiffness. In this paper, we review the emerging role of PON1 in the pathophysiology of atherosclerosis and arterial stiffness in patients with chronic kidney disease.
Collapse
|
19
|
She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal 2012; 16:597-632. [PMID: 21867409 PMCID: PMC3270057 DOI: 10.1089/ars.2010.3774] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The paraoxonase (PON) gene cluster contains three adjacent gene members, PON1, PON2, and PON3. Originating from the same fungus lactonase precursor, all of the three PON genes share high sequence identity and a similar β propeller protein structure. PON1 and PON3 are primarily expressed in the liver and secreted into the serum upon expression, whereas PON2 is ubiquitously expressed and remains inside the cell. Each PON member has high catalytic activity toward corresponding artificial organophosphate, and all exhibit activities to lactones. Therefore, all three members of the family are regarded as lactonases. Under physiological conditions, they act to degrade metabolites of polyunsaturated fatty acids and homocysteine (Hcy) thiolactone, among other compounds. By detoxifying both oxidized low-density lipoprotein and Hcy thiolactone, PONs protect against atherosclerosis and coronary artery diseases, as has been illustrated by many types of in vitro and in vivo experimental evidence. Clinical observations focusing on gene polymorphisms also indicate that PON1, PON2, and PON3 are protective against coronary artery disease. Many other conditions, such as diabetes, metabolic syndrome, and aging, have been shown to relate to PONs. The abundance and/or activity of PONs can be regulated by lipoproteins and their metabolites, biological macromolecules, pharmacological treatments, dietary factors, and lifestyle. In conclusion, both previous results and ongoing studies provide evidence, making the PON cluster a prospective target for the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Zhi-Gang She
- National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
| | | | | | | | | |
Collapse
|
20
|
Abstract
In this review we summarize the findings from the literature and our own laboratory on the decreased PON1 activity in renal failure, the mechanisms proposed and the effect of interventions. In addition to profound alterations in lipoproteins, reduced serum PON1 activity has been clearly established in the past decade and could contribute to accelerated development of atherosclerosis in ESRD and in HD. PON1 lactonase activity is lower in ESRD patients. Hemodialysis partially restores PON1 lactonase and the other activities. PON1 activity recovery after dialysis suggests that uremic toxins may play a mechanistic role in PON1 inactivation. Lower PON1 activity in CRF patients is associated with low thiol concentration, high CRP, and is beneficially enhanced with vitamin C and flavonoids. Changes in HDL subclasses, namely lower HDL3 in these patients may also play a role in PON1 lower activity. Future research should focus on: (1) mechanistic studies on causes for low PON1 activity and mass; (2) prospective studies focusing on whether there is an added predictive value in measuring PON1 activity (and PON1 activity in HDL3) in this patient population; (3) intervention studies attempting to increase PON1 activity.
Collapse
|
21
|
Căpuşă C, Mircescu G. Oxidative stress, renal anemia, and its therapies: is there a link? J Ren Nutr 2011; 20:S71-6. [PMID: 20797576 DOI: 10.1053/j.jrn.2010.06.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
In chronic kidney disease, anemia and oxidative stress are common features and both are involved in increasing morbidity and mortality. However, their relationship is still a matter of debate. This article is a review of published data and our experience and is intended to debate the pro and contra arguments concerning renal anemia and its 2 main therapeutic approaches, that are, erythropoietin and intravenous iron supplementation, as additional causes of oxidative stress in end-stage renal disease patients. To date, it seems more likely that renal anemia itself is the main contributor, and intravenous iron further enhances oxidative stress associated with chronic kidney disease. Future randomized prospective trials, with "hard" clinical end-points, are needed to establish the real effect of biochemical pro-oxidative changes on patient's outcome.
Collapse
Affiliation(s)
- Cristina Căpuşă
- Department of Nephrology, Dr. Carol Davila Teaching Hospital of Nephrology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
| | | |
Collapse
|
22
|
Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2010; 81:337-44. [PMID: 21093416 DOI: 10.1016/j.bcp.2010.11.008] [Citation(s) in RCA: 118] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2010] [Revised: 11/07/2010] [Accepted: 11/08/2010] [Indexed: 12/15/2022]
Abstract
Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)-associated enzyme displaying esterase and lactonase activity. PON1 hydrolyzes several organophosphorus (OP) insecticides and nerve agents, a number of exogenous and endogenous lactones, and metabolizes toxic oxidized lipids of low density lipoproteins (LDL) and HDL. As such, PON1 plays a relevant role in determining susceptibility to OP toxicity, cardiovascular diseases and several other diseases. Serum PON1 activity in a given population can vary by at least 40-fold. Most of this variation can be accounted for by genetic polymorphisms in the coding region (Q192R, L55M) and in the promoter region (T-108C). However, exogenous factors may also modulate PON1 activity and/or level of expression. This paper examines various factors that have been found to positively modulate PON1. Certain drugs (e.g. hypolipemic and anti-diabetic compounds), dietary factors (antioxidants, polyphenols), and life-style factors (moderate alcohol consumption) appear to increase PON1 activity. Given the relevance of PON1 in protecting from certain environmental exposure and from cardiovascular and other diseases, there is a need for further mechanistic, animal, and clinical research in this area, and for consideration of possible alternative strategies for increasing the levels and activity of PON1.
Collapse
Affiliation(s)
- Lucio G Costa
- Dept. of Environmental and Occupational Health Sciences, University of Washington, 4225 Roosevelt Way NE, Seattle, WA 98105, USA.
| | | | | |
Collapse
|
23
|
Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46:83-106. [PMID: 19255916 DOI: 10.1080/10408360802610878] [Citation(s) in RCA: 166] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Research into the paraoxonase (PON) gene family has flourished over the past few years. In the 1970s and 1980s, only PON1 was known, and the investigations were conducted, essentially, by toxicologists focusing on protection against organophosphate poisoning. Since then, two new members of the family, PON2 and PON3, have been identified, both being shown to play antioxidant and anti-inflammatory roles. Evidence exists indicating that the PON family is central to a wide variety of human illnesses such as cardiovascular disease, diabetes mellitus, metabolic syndrome, obesity, non-alcoholic steatohepatitis, and several mental disorders. However, research is hampered considerably by the methods currently available to measure the activity of these enzymes. In this review, we summarize the state of knowledge on PON biochemistry and function, the influence of genetic variations, and the involvement of PON in several diseases. The problems associated with PON measurement, such as sample acquisition, lack of reference methods, and variety of substrates, will be presented. Also, we cover some of the present lines of research and propose some others for future progress in this field.
Collapse
Affiliation(s)
- Jordi Camps
- Centre de Recerca Biomedica, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain.
| | | | | |
Collapse
|
24
|
De Vecchi AF, Bamonti F, Novembrino C, Ippolito S, Guerra L, Lonati S, Salini S, Aman CS, Scurati-Manzoni E, Cighetti G. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. Nephrol Dial Transplant 2009; 24:2524-9. [PMID: 19264746 DOI: 10.1093/ndt/gfp102] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Available data about oxidative status in patients with end-stage renal disease (ESRD) or on dialysis are contradictory. The present cross-sectional study aimed to investigate the role of renal insufficiency and dialysis on lipid peroxidation. To separate the effects of uraemia from dialysis-induced stress, we enrolled 26 patients with renal insufficiency on conservative treatment (ESRD), 23 on peritoneal dialysis (PD), 30 on haemodialysis (HD) and 30 controls. METHODS Plasma malondialdehyde (MDA) levels, both total (tMDA) and free (fMDA), were measured as indexes of oxidative stress by gas chromatography-mass spectrometry. Bound MDA (bMDA) levels were calculated as the difference between tMDA and fMDA. RESULTS Total and bMDA concentrations were significantly higher in patients than in controls (ESRD > HD > PD). In PD and HD patients, fMDA levels were similar and significantly higher than in ESRD. Multivariate analysis, with tMDA, fMDA and bMDA as dependent variables, showed similar and significant tMDA and bMDA relations with residual renal function (t = -2.160, P = 0.035) and albumin (t = -2.049, P = 0.045). Erythropoietin dose affected only fMDA values (t = -2.178, P = 0.034). CONCLUSIONS Free and bMDA concentrations identified different MDA patterns. Bound MDA, not excreted by kidneys, accounts alone for high tMDA concentrations in ESRD patients, while both fMDA and bMDA contribute to tMDA values in dialysis patients. These findings show that increased tMDA could be indicative not only of recent lipid peroxidation, and they also highlight the importance of evaluating free, bound and total MDA in patients with reduced renal function in order to assess their oxidative status.
Collapse
|
25
|
Kerkeni M, Letaief A, Achour A, Miled A, Trivin F, Maaroufi K. Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clin Biochem 2009; 42:777-82. [PMID: 19233152 DOI: 10.1016/j.clinbiochem.2009.02.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2008] [Revised: 02/09/2009] [Accepted: 02/09/2009] [Indexed: 11/24/2022]
Abstract
OBJECTIVES Hyperhomocysteinemia is associated with an increased risk of cardiovascular diseases. We determine homocysteine levels (Hcy), paraoxonase (PON1) concentration and their relationship on cardiovascular complications in patients with chronic renal disease (CRD). DESIGN AND METHODS The study population included 100 CRD patients and 120 healthy controls. Renal function was assessed using the eGFR by the MDRD study equation. Patients were considered to have CRD when the eGFR was <60 mL/min/1.73 m(2). Hcy concentrations were determined by direct chemiluminescence assay. PON1 concentration was measured spectrophotometrically using phenylacetate as a substrate. RESULTS We found an increased Hcy levels and a decreased eGFR and PON1 concentration in CRD patients compared to the control group (P<0.001, P<0.001, P<0.01 respectively). Patients with cardiovascular complications showed an increased Hcy levels and a lower PON1 concentration than patients without cardiovascular complications (P<0.001, P<0.01 respectively). CONCLUSION We showed that hyperhomocysteinemia and low PON1 concentration are associated with CRD and markedly associated in patients with cardiovascular complications. Additional effects contribute to the severity of renal disease and increase the incidence of cardiovascular disease.
Collapse
Affiliation(s)
- Mohsen Kerkeni
- Research Unit 03/UR/08-14, Faculty of Pharmacy, 5000-Monastir, Tunisia.
| | | | | | | | | | | |
Collapse
|